Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids

Ling Huang, Audrey Holtzinger, Ishaan Jagan, Michael Begora, Ines Lohse, Nicholas Ngai, Cristina Nostro, Rennian Wang, Lakshmi B. Muthuswamy, Howard C. Crawford, Cheryl Arrowsmith, Steve E. Kalloger, Daniel J. Renouf, Ashton A. Connor, Sean Cleary, David F. Schaeffer, Michael Roehrl, Ming Sound Tsao, Steven Gallinger, Gordon KellerSenthil K. Muthuswamy

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

There are few in vitro models of exocrine pancreas development and primary human pancreatic adenocarcinoma (PDAC). We establish three-dimensional culture conditions to induce the differentiation of human pluripotent stem cells into exocrine progenitor organoids that form ductal and acinar structures in culture and in vivo. Expression of mutant KRAS or TP53 in progenitor organoids induces mutation-specific phenotypes in culture and in vivo. Expression of TP53 R175H induces cytosolic SOX9 localization. In patient tumors bearing TP53 mutations, SOX9 was cytoplasmic and associated with mortality. We also define culture conditions for clonal generation of tumor organoids from freshly resected PDAC. Tumor organoids maintain the differentiation status, histoarchitecture and phenotypic heterogeneity of the primary tumor and retain patient-specific physiological changes, including hypoxia, oxygen consumption, epigenetic marks and differences in sensitivity to inhibition of the histone methyltransferase EZH2. Thus, pancreatic progenitor organoids and tumor organoids can be used to model PDAC and for drug screening to identify precision therapy strategies.

Original languageEnglish (US)
Pages (from-to)1364-1371
Number of pages8
JournalNature Medicine
Volume21
Issue number11
DOIs
StatePublished - Nov 1 2015
Externally publishedYes

Fingerprint

Organoids
Pluripotent Stem Cells
Preclinical Drug Evaluations
Stem cells
Pancreatic Neoplasms
Early Detection of Cancer
Tumors
Screening
Pharmaceutical Preparations
Neoplasms
Bearings (structural)
Exocrine Pancreas
Mutation
Human Development
Epigenomics
Oxygen Consumption
Oxygen
Adenocarcinoma
Phenotype
Mortality

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Huang, L., Holtzinger, A., Jagan, I., Begora, M., Lohse, I., Ngai, N., ... Muthuswamy, S. K. (2015). Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nature Medicine, 21(11), 1364-1371. https://doi.org/10.1038/nm.3973

Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. / Huang, Ling; Holtzinger, Audrey; Jagan, Ishaan; Begora, Michael; Lohse, Ines; Ngai, Nicholas; Nostro, Cristina; Wang, Rennian; Muthuswamy, Lakshmi B.; Crawford, Howard C.; Arrowsmith, Cheryl; Kalloger, Steve E.; Renouf, Daniel J.; Connor, Ashton A.; Cleary, Sean; Schaeffer, David F.; Roehrl, Michael; Tsao, Ming Sound; Gallinger, Steven; Keller, Gordon; Muthuswamy, Senthil K.

In: Nature Medicine, Vol. 21, No. 11, 01.11.2015, p. 1364-1371.

Research output: Contribution to journalArticle

Huang, L, Holtzinger, A, Jagan, I, Begora, M, Lohse, I, Ngai, N, Nostro, C, Wang, R, Muthuswamy, LB, Crawford, HC, Arrowsmith, C, Kalloger, SE, Renouf, DJ, Connor, AA, Cleary, S, Schaeffer, DF, Roehrl, M, Tsao, MS, Gallinger, S, Keller, G & Muthuswamy, SK 2015, 'Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids', Nature Medicine, vol. 21, no. 11, pp. 1364-1371. https://doi.org/10.1038/nm.3973
Huang, Ling ; Holtzinger, Audrey ; Jagan, Ishaan ; Begora, Michael ; Lohse, Ines ; Ngai, Nicholas ; Nostro, Cristina ; Wang, Rennian ; Muthuswamy, Lakshmi B. ; Crawford, Howard C. ; Arrowsmith, Cheryl ; Kalloger, Steve E. ; Renouf, Daniel J. ; Connor, Ashton A. ; Cleary, Sean ; Schaeffer, David F. ; Roehrl, Michael ; Tsao, Ming Sound ; Gallinger, Steven ; Keller, Gordon ; Muthuswamy, Senthil K. / Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. In: Nature Medicine. 2015 ; Vol. 21, No. 11. pp. 1364-1371.
@article{239fe83a4ceb427193ea9f66af531236,
title = "Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids",
abstract = "There are few in vitro models of exocrine pancreas development and primary human pancreatic adenocarcinoma (PDAC). We establish three-dimensional culture conditions to induce the differentiation of human pluripotent stem cells into exocrine progenitor organoids that form ductal and acinar structures in culture and in vivo. Expression of mutant KRAS or TP53 in progenitor organoids induces mutation-specific phenotypes in culture and in vivo. Expression of TP53 R175H induces cytosolic SOX9 localization. In patient tumors bearing TP53 mutations, SOX9 was cytoplasmic and associated with mortality. We also define culture conditions for clonal generation of tumor organoids from freshly resected PDAC. Tumor organoids maintain the differentiation status, histoarchitecture and phenotypic heterogeneity of the primary tumor and retain patient-specific physiological changes, including hypoxia, oxygen consumption, epigenetic marks and differences in sensitivity to inhibition of the histone methyltransferase EZH2. Thus, pancreatic progenitor organoids and tumor organoids can be used to model PDAC and for drug screening to identify precision therapy strategies.",
author = "Ling Huang and Audrey Holtzinger and Ishaan Jagan and Michael Begora and Ines Lohse and Nicholas Ngai and Cristina Nostro and Rennian Wang and Muthuswamy, {Lakshmi B.} and Crawford, {Howard C.} and Cheryl Arrowsmith and Kalloger, {Steve E.} and Renouf, {Daniel J.} and Connor, {Ashton A.} and Sean Cleary and Schaeffer, {David F.} and Michael Roehrl and Tsao, {Ming Sound} and Steven Gallinger and Gordon Keller and Muthuswamy, {Senthil K.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1038/nm.3973",
language = "English (US)",
volume = "21",
pages = "1364--1371",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids

AU - Huang, Ling

AU - Holtzinger, Audrey

AU - Jagan, Ishaan

AU - Begora, Michael

AU - Lohse, Ines

AU - Ngai, Nicholas

AU - Nostro, Cristina

AU - Wang, Rennian

AU - Muthuswamy, Lakshmi B.

AU - Crawford, Howard C.

AU - Arrowsmith, Cheryl

AU - Kalloger, Steve E.

AU - Renouf, Daniel J.

AU - Connor, Ashton A.

AU - Cleary, Sean

AU - Schaeffer, David F.

AU - Roehrl, Michael

AU - Tsao, Ming Sound

AU - Gallinger, Steven

AU - Keller, Gordon

AU - Muthuswamy, Senthil K.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - There are few in vitro models of exocrine pancreas development and primary human pancreatic adenocarcinoma (PDAC). We establish three-dimensional culture conditions to induce the differentiation of human pluripotent stem cells into exocrine progenitor organoids that form ductal and acinar structures in culture and in vivo. Expression of mutant KRAS or TP53 in progenitor organoids induces mutation-specific phenotypes in culture and in vivo. Expression of TP53 R175H induces cytosolic SOX9 localization. In patient tumors bearing TP53 mutations, SOX9 was cytoplasmic and associated with mortality. We also define culture conditions for clonal generation of tumor organoids from freshly resected PDAC. Tumor organoids maintain the differentiation status, histoarchitecture and phenotypic heterogeneity of the primary tumor and retain patient-specific physiological changes, including hypoxia, oxygen consumption, epigenetic marks and differences in sensitivity to inhibition of the histone methyltransferase EZH2. Thus, pancreatic progenitor organoids and tumor organoids can be used to model PDAC and for drug screening to identify precision therapy strategies.

AB - There are few in vitro models of exocrine pancreas development and primary human pancreatic adenocarcinoma (PDAC). We establish three-dimensional culture conditions to induce the differentiation of human pluripotent stem cells into exocrine progenitor organoids that form ductal and acinar structures in culture and in vivo. Expression of mutant KRAS or TP53 in progenitor organoids induces mutation-specific phenotypes in culture and in vivo. Expression of TP53 R175H induces cytosolic SOX9 localization. In patient tumors bearing TP53 mutations, SOX9 was cytoplasmic and associated with mortality. We also define culture conditions for clonal generation of tumor organoids from freshly resected PDAC. Tumor organoids maintain the differentiation status, histoarchitecture and phenotypic heterogeneity of the primary tumor and retain patient-specific physiological changes, including hypoxia, oxygen consumption, epigenetic marks and differences in sensitivity to inhibition of the histone methyltransferase EZH2. Thus, pancreatic progenitor organoids and tumor organoids can be used to model PDAC and for drug screening to identify precision therapy strategies.

UR - http://www.scopus.com/inward/record.url?scp=84946215806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946215806&partnerID=8YFLogxK

U2 - 10.1038/nm.3973

DO - 10.1038/nm.3973

M3 - Article

AN - SCOPUS:84946215806

VL - 21

SP - 1364

EP - 1371

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 11

ER -